Emerging CNS Ailments Target neurodegenerative disease treatments through CNS-focused device systems that Access, Recirculate & Modify CSF, highlighting a need for strategic outreach to neurology-focused hospitals, research centers, and specialty clinics.

Compact, High-Impact Small team size suggests agility but potential capacity constraints; position as a preferred technology partner for early-stage pilots, clinical collaborations, and co-development opportunities to accelerate development timelines.

Funding Momentum Recent Series A funding and notable investors (20/20 HCP, Peter Thiel, Amgen Ventures, Presight, Dolby Ventures) indicate strong credibility; leverage as a talking point to engage potential customers and strategic partners seeking proven innovation.

Device-based Therapeutics Offers semi-permanent, pacemaker-sized pumps and targeted CSF filtration to remove toxic proteins; explore sales opportunities with neurology departments, CNS treatment centers, and integrated delivery systems seeking intracerebral CSF interventions.

Early-Stage Revenue Revenue in the lower mid-range and ongoing product development imply a focus on partnerships, pilots, and field trials; propose structured engagements such as joint development agreements or early-access programs to accelerate market validation.